Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Abstract Text:

Baron,Rainer Storb,

PURPOSE OF REVIEW: Allogeneic hematopoietic cell transplantation with myeloablative conditioning is a well established therapy for patients with acute myeloid leukemia. Its efficacy depends, in part, on the destruction of recipient acute myeloid leukemia cells by the conditioning regimen and, in part on their removal by donor immune cells contained in the graft (graft-versus-tumor effect). Due to regimen-related toxicities, the use of myeloablative allogeneic hematopoietic cell transplantation has been restricted to younger patients in good condition. More recently, the introduction of allogeneic hematopoietic cell transplantation following reduced-intensity or nonmyeloablative conditioning regimens, which rely mainly on graft-versus-tumor effects for tumor cell eradication, has permitted extending hematopoietic cell transplantation to include older patients and those with medical comorbidities. RECENT FINDINGS: Early results with allogeneic hematopoietic cell transplantation after nonmyeloablative and reduced-intensity conditioning for patients with acute myeloid leukemia in first complete remission are encouraging, with 2-year survivals after hematopoietic cell transplantation ranging from 48 to 79% among studies. Further, retrospective studies have demonstrated similar outcomes in adult patients with acute myeloid leukemia in complete remission given either myeloablative or nonmyeloablative conditioning. SUMMARY: Prospective studies are needed to define the place of allogeneic hematopoietic cell transplantation after nonmyeloablative or reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission, and to determine a role for consolidation chemotherapy before hematopoietic cell transplantation, if any.

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Publishing Authors By Initials

F Baron,R Storb,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Journal Published:

PUBLICATION TYPE: Review

Journal: Current opinion in hematology

VOLUME: 14

Page Numbers: 145-51

Journal Abbreviation: Curr. Opin. Hematol.

ISSN: 1065-6251

DAY: 3

MONTH: Mar

YEAR: 2007

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Information

Number of References: 41

LANGUAGE: eng

NlmUniqueID: 9430802

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: methods

Chemical & Substance for Abstract: Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.

AFFILIATION: University of Liège, Liège, Belgium.

Country: United States

AGENCY: United States NHLBI

GRANT: HL36444

ACRONYM: HL

MEDLINETA: Curr Opin Hematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission Related Publications

• Alkyladenine DNA glycosylase (Aag) in somatic hypermutation and class switch recombination.
• An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88*01101 and DLA-88*01201.
• Brca1 in immunoglobulin gene conversion and somatic hypermutation.
• Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.
• Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model.
• Development and in vitro characterization of canine CD40-Ig.
• Donor-specific mononuclear cell transfusion and methotrexate as pretransplant treatment in dogs given DLA-identical marrow grafts after nonmyeloablative conditioning.
• Expression of AID transgene is regulated in activated B cells but not in resting B cells and kidney.
• Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
• Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation.
• Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation.
• Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs.
• Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission.
• Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.
• Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.
• Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia.
• Long-term tolerance to kidney allografts in a preclinical canine model.
• Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
• Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.
• Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy.
• Principles of peripheral blood mononuclear cell apheresis in a preclinical canine model of hematopoietic cell transplantation.
• Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
• Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
• Scarcity of lambda 1 B cells in mice with a single point mutation in C lambda 1 is due to a low BCR signal caused by misfolded lambda 1 light chain.
• Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
• Somatic hypermutation and class switch recombination in Msh6(-/-)Ung(-/-) double-knockout mice.
• Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning.
• Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
• The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective.
• Treatment of acute leukemia in remission by bone marrow transplantation.